0001104659-20-068501.txt : 20200601
0001104659-20-068501.hdr.sgml : 20200601
20200601173204
ACCESSION NUMBER: 0001104659-20-068501
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200601
FILED AS OF DATE: 20200601
DATE AS OF CHANGE: 20200601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lindborg Stacy
CENTRAL INDEX KEY: 0001813667
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36641
FILM NUMBER: 20934876
MAIL ADDRESS:
STREET 1: C/O BRAINSTORM CELL THERAPEUTICS, INC.
STREET 2: 1325 AVENUE OF AMERICAS, 28TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC.
CENTRAL INDEX KEY: 0001137883
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 207273918
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1325 AVENUE OF AMERICAS
STREET 2: 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 201-488-0460
MAIL ADDRESS:
STREET 1: 1325 AVENUE OF AMERICAS
STREET 2: 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 20041122
FORMER COMPANY:
FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC
DATE OF NAME CHANGE: 20030827
FORMER COMPANY:
FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC
DATE OF NAME CHANGE: 20010409
4
1
tm2021119-2_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-06-01
0
0001137883
BRAINSTORM CELL THERAPEUTICS INC.
BCLI
0001813667
Lindborg Stacy
C/O BRAINSTORM CELL THERAPEUTICS INC.
1325 AVENUE OF AMERICAS, 28TH FLOOR
NEW YORK
NY
10019
0
1
0
0
EVP, Head Global Clin Research
Common Stock
2020-06-01
4
A
0
25000
0
A
25000
D
Stock Option (right to buy)
7.67
2020-06-01
4
A
0
100000
0
A
2021-02-28
2030-06-01
Common Stock
100000
100000
D
Shares acquired are shares of restricted stock awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on December 31, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date.
The option, awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan, shall vest and become exercisable as to 50,000 of the underlying shares on February 28, 2021 ("First Vesting Date"), and the remaining 50,000 shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter until fully vested and exercisable on the second anniversary of the First Vesting Date, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.
/s/ Nathaniel Gaede (Pursuant to Power of Attorney)
2020-06-01